| Ytd | -7.45% | |
| 1y | 693.96% |
| Open | 4.55 | Prev Close | 4.54 | Low | 4.36 | High | 4.62 | Mkt Cap | 468.86M |
| Vol | 2.15M | Avg Vol | 1.75M | EPS | -1.09 | P/E | -4.10 | Forward P/E | -0.19 |
| Beta | 0.41 | Short Ratio | 4.52 | Inst. Own | 46.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 6.03 | 200-d Avg | 5.31 | 1yr Est | 0.87 |
RLMD News
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure
Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its s
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Novo Nordisk A/S (NYSE: NVO - Get Free Rep
ADAR1 Capital Management LLC increased its holdings in Relmada Therapeutics, Inc. (NASDAQ: RLMD) by
CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) was the recipient of a large growth in s
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. (NASDAQ:RLMD) with a prim
Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Chec
CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock
US stock futures surge on tech sector news, HPE reports strong earnings, and other tech stocks follo
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relm
Relmada Therapeutics NASDAQ: RLMD said it remains on track to begin its Phase 3 RESCUE registrationa
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relm
CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relm
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may p
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the
US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving l
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 12
Gainers Nutex Health Inc. (NASDAQ: NUTX) jumped 72.4% to settle at $0.9551 on Thursday. Nutex Hea
On Tuesday, 951 companies hit new 52-week lows.
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report